11/3/2026

speaker
Joel
Conference Call Operator

Good afternoon and welcome to Mirim Pharmaceuticals' third quarter 2026 earnings conference call. My name is Joel and I will be your operator today. All lines are currently in a listen-only mode and there will be an opportunity for Q&A after management's prepared remarks. I would now like to hand the conference over to Andrew McKibben, SVP of Strategic Finance and Investor Relations. Please go ahead.

speaker
Andrew McKibben
SVP, Strategic Finance and Investor Relations

Thank you, Joel, and good afternoon, everyone. I'd like to welcome you to Miriam Pharmaceuticals' third quarter of 2026 conference call. I'm joined today by our Chief Executive Officer, Chris Peetz, our President and Chief Operating Officer, Peter Radovich, our Chief Medical Officer, Rob Myers, and our Chief Financial Officer, Eric Bjerkholt. Earlier today, Miriam issued a press release announcing the company's results for the third quarter of 2026. Copies of the press release and our SEC filings are available on the Investors section of our website. Before we start, I'd like to remind you that during the course of this conference call, we'll be making certain forward-looking statements based on management's current expectations, including statements regarding Merrim's programs and market opportunities for its approved medicines and product candidates, and financial guidance. These statements represent our judgment and knowledge of events as of today and inherently involve risks and uncertainties that may cause actual results to differ materially from the results discussed. We are under no duty to update these statements. Please refer to the risk factors in our latest Form 10-Q and subsequent SEC filings for more information about these risks and uncertainties. With that, I'd like to turn the call over to Chris. Chris?

speaker
Chris Peetz
Chief Executive Officer

Thanks, Andrew. Third quarter was another strong period for Mira, both commercially and across our clinical programs. We generated $186 million in third quarter net product sales. We are increasing our full year net product sales guidance to $715 to $720 million. We've also had great progress across the portfolio since our last earnings call. Positive phase three is your one data for Brilovitug, positive expand data for the Marley, the approval and launch of Atebrios, and another positive Atebrios readout in younger patients. Our recent progress feels quite meaningful as Mirim approaches its eighth anniversary. It's remarkable to think about what this team has accomplished in eight years. We started Mirim around a simple idea. that by identifying important opportunities in rare diseases and combining great medicines with relentless execution, we could have a meaningful impact for patients and build an enduring company. Eight years later, we now have four approved medicines, a commercial business approaching three quarters of a billion dollars in annual net product sales, and a late stage pipeline with multiple opportunities to drive our next phase of growth. Coming up, we have two more potentially registrational readouts approaching, with the Dorlevitug-04 study and HTV expected this quarter and the Belixibat-Vantage study and PBC expected in the first quarter of next year. Together, these are part of five potential approvals and label expansions ahead of us as we work towards realizing the greater than $4 billion peak revenue potential of the Mirim portfolio. So, eight years in, we're entering our next phase from a position of real strength, and we're excited to touch on some highlights and updates today. With that, I'll turn the call over to Peter. Peter? Thanks, Chris.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation